187
Participants
Start Date
May 31, 2016
Primary Completion Date
November 30, 2024
Study Completion Date
December 31, 2026
aglatimagene besadenovec
Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
placebo
Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
valacyclovir
Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
Advanced Radiation Centers of New York (Integrated Medical Professionals), North Hills
Associated Medical Professionals of NY, PLLC, Syracuse
Allegheny Health Network-Triangle Urological Group, Pittsburgh
Lancaster Urology, Lancaster
Walter Reed National Military Medical Center, Bethesda
Hunter Holmes McGuire VA Medical Center, Richmond
Salem VA Medical Center, Salem
Ralph H. Johnson Veterans Affairs Medical Center, Charleston
Southwest Urology, Clinical Research Solutions, Middleburg Heights
Jesse Brown VA Medical Center, Chicago
The University of Chicago, Chicago
Kansas City VA Medical Center, Kansas City
Southeast Louisiana Veterans Health Care System, New Orleans
Oklahoma City VA Healthcare System, Oklahoma City
Texas Urology Specialists, Tomball
Woodland Center, The Woodlands
Foothills Urology, Golden
Sierra Nevada Health Care System VA, Reno
VA Portland Health Care System, Portland
Oregon Urology Insitute, Springfield
Hackensack University Medical Center, Hackensack
San Antonio VA Healthcare System, San Antonio
Instituto Nacional de Ciencias Medicas y Nutrición, Salvador Subirán, Mexico City
Lead Sponsor
Candel Therapeutics, Inc.
INDUSTRY